Takeda Pharmaceutical Company Limited
As of Oct 23, 2026 close
- Market cap
- $64.96B
- P/E (TTM)
- 56.52
- Forward P/E
- 58.94
- Dividend yield
- 1.51%
- 52-week range
- $12.99$20.13
- Volume (live)
- -
- Avg. volume (3M)
- 2.55M
Takeda Pharmaceutical Company (TAK) Stock Price & Financial Analysis
Takeda Pharmaceutical Company Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $20.17 - $20.39 |
|---|---|
| 52-Week High | $20.13 |
| 52-Week Low | $12.99 |
| Open | $20.28 |
| Volume (last close) | 2.10M |
| Average Volume (3M) | 2.55M |
| Revenue (TTM) | 29.58B |
|---|---|
| Net Income (TTM) | 1.15B |
| Free Cash Flow (TTM) | 2.84B |
| EPS (TTM) | $0.41 |
| Profit Margin | 3.89% |
| Operating Margin | 12.67% |
| Return on Equity (ROE) | 2.39% |
| Debt to Equity | 0.65 |
| Annual Dividend | $0.71 |
|---|---|
| Dividend Yield | 1.51% |
| Payout Ratio | 74.55% |
| Last Dividend Ex-Date | Sep 29, 2026 |
| Market Cap | 64.96B |
|---|---|
| Shares Outstanding | 3.21B |
| P/E Ratio (TTM) | 56.52 |
| Forward P/E | 58.94 |
| Price to Sales (P/S) | 2.20 |
| Price to Book (P/B) | 1.35 |
| EV/EBITDA | 11.34 |
| 50-Day MA | $18.43 |
|---|---|
| 200-Day MA | $17.38 |
| 1-Year Change | +44.81% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Takeda Pharmaceutical Company at a Glance
As of the Oct 23, 2026 close, Takeda Pharmaceutical Company (TAK) has a market capitalization of $64.96B. The stock trades at 56.5× trailing earnings, 58.9× forward earnings and 2.2× sales. Over the trailing twelve months it earned $1.15B on revenue of $29.58B (a 3.9% profit margin) and generated $2.84B of free cash flow. Revenue grew 3.1% year over year.
As of its latest reported balance sheet, it holds $2.94B in cash and securities against $31.50B of debt, a net debt position of $28.56B.
Takeda Pharmaceutical Company pays dividends totaling $0.71 per share a year, a 1.51% yield at the Oct 23, 2026 close, with a 75% payout ratio and 3 consecutive years of dividend increases.
The share price is up 44.8% over the past year. At $20.24 (the Oct 23, 2026 close) it sits near the top of its 52-week range of $12.99 to $20.13, above its 200-day moving average of $17.38.
Based on 1 professional analyst rating from the past 90 days, the consensus is Buy.
Frequently Asked Questions About Takeda Pharmaceutical Company
What is the current stock price for TAK?
As of the Oct 23, 2026 close, TAK stock trades at $20.24. The 52-week range is $12.99–$20.13, with a day range of $20.17–$20.39.
What is the P/E ratio for TAK?
As of the Oct 23, 2026 close, Takeda Pharmaceutical Company's trailing twelve-month (TTM) P/E ratio is 56.5, meaning investors pay $56.5 for every $1 of annual earnings. The forward P/E is 58.9, reflecting analyst expectations for future earnings. Takeda Pharmaceutical Company operates in the Healthcare sector.
Does TAK pay dividends?
Yes, Takeda Pharmaceutical Company pays a 1.51% annual dividend yield as of the Oct 23, 2026 close ($0.71 per share a year). The trailing twelve-month payout ratio is 74.5%. The most recent ex-dividend date was September 29, 2026.
What do analysts recommend for TAK?
Based on ratings from 1 professional analyst over the last 90 days, the consensus for TAK is Buy.
What is the market cap of TAK?
As of the Oct 23, 2026 close, Takeda Pharmaceutical Company's market capitalization is $64.96B, classifying it as a large-cap company. Takeda Pharmaceutical Company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.